• Impax Laboratories Inc., of Hayward, Calif., and Tolmar Therapeutics Inc., of Ft. Collins, Colo., said the FDA granted final approval of Tolmar’s abbreviated new drug application for its generic version of Solaraze Gel (diclofenac sodium 3 percent).